GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MannKind Corp (NAS:MNKD) » Definitions » Sloan Ratio %

MannKind (MannKind) Sloan Ratio % : -9.27% (As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is MannKind Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

MannKind's Sloan Ratio for the quarter that ended in Dec. 2023 was -9.27%.

As of Dec. 2023, MannKind has a Sloan Ratio of -9.27%, indicating the company is in the safe zone and there is no funny business with accruals.


MannKind Sloan Ratio % Historical Data

The historical data trend for MannKind's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MannKind Sloan Ratio % Chart

MannKind Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Sloan Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 63.40 -40.81 41.20 -3.93 -9.27

MannKind Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.93 -22.84 -25.70 -19.43 -9.27

Competitive Comparison of MannKind's Sloan Ratio %

For the Biotechnology subindustry, MannKind's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MannKind's Sloan Ratio % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MannKind's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where MannKind's Sloan Ratio % falls into.



MannKind Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

MannKind's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2023 )-Cash Flow from Operations (A: Dec. 2023 )
-Cash Flow from Investing (A: Dec. 2023 ))/Total Assets (A: Dec. 2023 )
=(-11.938-34.094
--1.988)/475.198
=-9.27%

MannKind's Sloan Ratio for the quarter that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Dec. 2023 )
=(-11.938-34.094
--1.988)/475.198
=-9.27%

MannKind's Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was -9.795 (Mar. 2023 ) + -5.265 (Jun. 2023 ) + 1.721 (Sep. 2023 ) + 1.401 (Dec. 2023 ) = $-11.9 Mil.
MannKind's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 was 1.156 (Mar. 2023 ) + 2.596 (Jun. 2023 ) + 8.664 (Sep. 2023 ) + 21.678 (Dec. 2023 ) = $34.1 Mil.
MannKind's Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 was 13.792 (Mar. 2023 ) + 3.664 (Jun. 2023 ) + -11.549 (Sep. 2023 ) + -7.895 (Dec. 2023 ) = $-2.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MannKind  (NAS:MNKD) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Dec. 2023, MannKind has a Sloan Ratio of -9.27%, indicating the company is in the safe zone and there is no funny business with accruals.


MannKind Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of MannKind's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


MannKind (MannKind) Business Description

Traded in Other Exchanges
Address
1 Casper Street, Danbury, CT, USA, 06810
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
Executives
Michael Castagna officer: Chief Commercial Officer 25134 RYE CANYON LOOP, SUITE 300, VALENCIA CA 91355
David Thomson officer: VP & Assoc General Counsel 28903 NORTH AVENUE PAINE, VALENCIA CA 91355
Steven B. Binder officer: Chief Financial Officer 30930 RUSSELL RANCH ROAD, SUITE 300, WESTLAKE VILLAGE CA 91362
Burkhard Blank officer: EVP Chief Medical Officer C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Lauren M Sabella officer: EVP Chief Operating Officer C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Sanjay R Singh officer: EVP Technical Operations 1 CASPER STREET, DANBURY CT 06810
Alejandro Galindo officer: Chief Commercial Officer 30930 RUSSELL RANCH RD, STE 300, WESTLAKE VILLAGE CA 91362
Stuart A Tross officer: Corp VP, Chief People Officer ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Anthony C Hooper director AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Jennifer Grancio director 30930 RUSSELL RANCH ROAD SUITE 300, WESTLAKE VILLAGE CA 91362
Christine Mundkur director
Sabrina Kay director 30930 RUSSELL RANCH ROAD, SUITE 300, WESTLAKE VILLAGE CA 91362
David M Kendall officer: Chief Medical Officer 30930 RUSSELL RANCH ROAD, WESTLAKE VILLAGE CA 91362
Patrick Mccauley officer: Chief Commercial Officer 30930 RUSSELL RANCH ROAD, SUITE 300, WESTLAKE VILLAGE CA 91362
Barton Courtney officer: Chief Compliance Officer 30930 RUSSELL RANCH ROAD, WESTLAKE VILLAGE CA 91362